EOLS Quote, Financials, Valuation and Earnings

Electromed has a net margin of -31.38% compared to Evolus's net margin of 10.05%. Evolus's return on equity of -7724.23% beat Electromed's return on equity of 15.62%.

Evolus has a consensus price target of $23.43, signalling upside risk potential of 134.29%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 10.85%. Given that Evolus has higher upside potential than Electromed, analysts believe Evolus is more attractive than Electromed.

Evolus has a beta of 1.324, which suggesting that the stock is 32.389% more volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

Evolus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Evolus quarterly revenues are $61.1M, which are larger than Electromed quarterly revenues of $14.7M. Evolus's net income of -$19.2M is lower than Electromed's net income of $1.5M. Notably, Evolus's price-to-earnings ratio is -- while Electromed's PE ratio is 41.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus is 2.44x versus 4.65x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -31.38% compared to Evolus's net margin of -10.5%. Evolus's return on equity of -7724.23% beat Myomo's return on equity of -84.04%.

Evolus has a consensus price target of $23.43, signalling upside risk potential of 134.29%. On the other hand Myomo has an analysts' consensus of -- which suggests that it could grow by 17.77%. Given that Evolus has higher upside potential than Myomo, analysts believe Evolus is more attractive than Myomo.

Evolus has a beta of 1.324, which suggesting that the stock is 32.389% more volatile than S&P 500. In comparison Myomo has a beta of 1.719, suggesting its more volatile than the S&P 500 by 71.909%.

Evolus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Evolus quarterly revenues are $61.1M, which are larger than Myomo quarterly revenues of $9.2M. Evolus's net income of -$19.2M is lower than Myomo's net income of -$966.4K. Notably, Evolus's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus is 2.44x versus 9.51x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -31.38% compared to Evolus's net margin of 14.25%. Evolus's return on equity of -7724.23% beat Insulet's return on equity of 49.55%.

Evolus has a consensus price target of $23.43, signalling upside risk potential of 134.29%. On the other hand Insulet has an analysts' consensus of $292.08 which suggests that it could grow by 7.45%. Given that Evolus has higher upside potential than Insulet, analysts believe Evolus is more attractive than Insulet.

Evolus has a beta of 1.324, which suggesting that the stock is 32.389% more volatile than S&P 500. In comparison Insulet has a beta of 1.218, suggesting its more volatile than the S&P 500 by 21.787%.

Evolus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Evolus quarterly revenues are $61.1M, which are smaller than Insulet quarterly revenues of $543.9M. Evolus's net income of -$19.2M is lower than Insulet's net income of $77.5M. Notably, Evolus's price-to-earnings ratio is -- while Insulet's PE ratio is 46.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus is 2.44x versus 10.47x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -31.38% compared to Evolus's net margin of -17.98%. Evolus's return on equity of -7724.23% beat Xtant Medical Holdings's return on equity of -35.98%.

Evolus has a consensus price target of $23.43, signalling upside risk potential of 134.29%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 351.1%. Given that Xtant Medical Holdings has higher upside potential than Evolus, analysts believe Xtant Medical Holdings is more attractive than Evolus.

Evolus has a beta of 1.324, which suggesting that the stock is 32.389% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

Evolus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Evolus quarterly revenues are $61.1M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. Evolus's net income of -$19.2M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Evolus's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus is 2.44x versus 0.58x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.